Annabel Samimy: Hi, thanks for taking my question. I had a couple. So I guess with the greater experience that physicians are having and more understanding of this rare event, do you notice a change in the way physicians are selecting their patients? I know that you had identified some low hanging fruit initially. Have they become more selective in their use since those events or is the comfort level now increasing and they’re becoming a little bit more liberal with their use and maybe moving to less severe patients? So just to add a little bit of color around the type of patient selection physicians have? And then secondly, was wondering if there is any moment where you’d be comfortable giving guidance on SYFOVRE sales going forward? Thanks.
Cedric Francois: Thank you so much, Annabel, and Caroline.
Caroline Baumal: Thank you. I think physicians are very enthusiastic about SYFOVRE and they understand whenever we present about the large robust data set that we have and the clinical findings, they understand the science and that’s and that’s really what drives them. What we have seen is that physicians may be a little more conservative than they were in the beginning. For example, not treating both eyes first visit or starting with the worst eye first which is not uncommon from intravisual injections, but they are very comfortable now with the technique of drop of the product which is slightly thicker and they have continued their use with enthusiasm. Adam, do you have anything to add to that?
Adam Townsend: Yes. Thanks for the question, Annabel. Just to add to Caroline’s comments, right, I think, you the graph in the presentation in October we’re seeing demand trajectory eclipse and back to the July levels, right? And one thing I love about this is that we’re seeing new patients come on to SYFOVRE every week and that to me is a really solid signal of confidence. I gave this metric earlier, I’ll give it again because it excites me. It’s every week since launch we’ve had double digit new accounts start and order SYFOVRE for the first time. And I think that’s a very positive, positive thing. And now with the J-code, I expect us to continue to drive that. But as Caroline said, it was a little bit of a pause in terms of how people use the drug and I think we’re starting to make inroads, that confidence is coming back into the community.
Tim Sullivan: Sure. And I’ll just jump in on guidance. I don’t know when we plan to give any guidance. What I will say is that if you’d asked me where we were three months ago and where we are today, I’m really excited and I think the more we can get the next couple of quarters under our feet, we’ll have a really good sense of where we are. I don’t know when we’ll actually give guidance. It’s something we haven’t committed to, but we’ll let you know when we have a decision on that.
Annabel Samimy: Okay, great. Thank you.
Cedric Francois: Thank you.
Operator: Thank you. [Operator Instructions] Our next question is coming from the line of Douglas Tsao with H.C. Wainwright. Your line is open.
Douglas Tsao: Good morning. Sorry about that. Good morning and thanks for taking the question. I guess, Adam, I wanted to touch on something that you commented and we talked about it before in terms of patient interest and demand. I’m just curious how are you trying to overcome perhaps, physician, I don’t want to say resistance, but sort of hesitation to start treatment for any number of reasons, safety or some docs aren’t necessarily fully convinced on the efficacy in the face of sort of trying to get patients to get treated, because it seems like sometimes I’ve been talking to doctors, they speak about patient enthusiasm and they say that they’re sort of trying to pump the brakes on their patients. And how are you trying to sort of get docs to ease up on that? Or is it a matter of trying to just redirect patients to doctors who are more readily treating with SYFOVRE? Thank you.
Adam Townsend: Yes. Thanks Doug for the question. So yes, interestingly pre-launch of SYFOVRE did a lot of, we spent a lot of time with GA patients and they were super enthusiastic about our potential treatment. They used to give us anecdotes like, I want to spend time with my grandkids and be able to read to them and all of those type of activities, that has not changed since launch. This is a very driven patient population. We are obviously doing some commercial activities to help patients flag that they may have vision impairment and they should go and see a retina physician or an ophthalmologist or an optometrist through our TV and radio campaign with Henry Winkler. I think that’s had a very positive impact in the market.
That has driven patients into physicians. We’ve also started to see that physicians can now have a benefit risk discussion with these patients and the patient motivation has an impact on that prescribing physician. So we’ll continue to do more activities to drive patients. We have found that if some physicians are for whatever reasons, not injecting SYFOVRE that these patients will seek other physicians that are. So that’s happening within the market. But this is a highly, highly motivated patient population and it meets in an incredibly good discussion of highly motivated physician conversation.
Douglas Tsao: Great. And if I can ask one follow up, I know there’s been a lot of focus on the third, third, third sort of market research that you had talked about from the summer. I’m just curious to your sense of the third who had sort of stopped using or weren’t using, do you think some of those were just physicians or how many of them were just doctors or just for whatever reason, we’re never going to be big users and so that you’re sort of right now sort of really sort of hitting a good part of the sort of truly receptive market? Thank you.
Adam Townsend: Yes, thanks Doug. So again if I jump back to pre-SYFOVRE relaunch, we always had a segment of physicians who said, I’m not going to use your drug until the permanent J-code. So there was an assumption in our third, a third, a third that that segment that said we’re not going to use your drug, basically also included those physicians who were waiting for the J-code. So I think we potentially will see an impact within that segment and have seen an impact within that segment in the last quarter. I think the more transparent we can be, the more transparent we can be, the more open we can be, but also now we’re pushing our efficacy message with physicians, I think it unlocks all of those segments and we started to see those segments unlocked with the strong demand levels that we’ve had since for this quarter and moving forward. So I think it’s going to be a very positive next couple of quarters.
Douglas Tsao: Okay, great. Thanks and congrats on the progress.
Adam Townsend: Thank you.
Operator: Thank you. One moment for our next question. And our next question is coming from the line of Joseph Stringer with Needham. Your line is open.
Joseph Stringer: Hi, thanks for taking our question. Just following up on the last two questions for the physicians who are not currently injecting SYFOVRE for safety reasons, is it your sense to say that rate of vasculitis is the sticking point or is it more physicians are comfortable with the rate and it’s more a matter of, they want to see the total number of patients or the total number of injections a lot higher before they would start injecting? And is there a threshold number of patients or injections if that they would need to see to get more comfortable if that is the case before injecting?
Cedric Francois: Yes. I think, Joey, thank you so much for that question. It’s important to bear in mind that this rate in itself was never an issue, right? I mean, the problem that we had is that a couple of years ago, there was another drug that started with this rate and ended up with a rate that was orders of magnitude worse, because there was a sensitization against the drug. This is absolutely not the case here. So this is an extremely rare event sporadically over time. And as I mentioned, we’re going to keep tracking that, but it is a very straightforward conversation now between the physician and the patient. Adam, can maybe comment briefly on the commercial impact of that.
